P005: Head-to-head trial of pegunigalsidase alfa vs agalsidase beta in Fabry disease: Phase 3 randomized, double-blind, BALANCE Study 2-year results

P005: Head-to-head trial of pegunigalsidase alfa vs agalsidase beta in Fabry disease: Phase 3 randomized, double-blind, BALANCE Study 2-year results

Bibliographic Details
Main Authors:	John Bernat, Eric Wallace, Ozlem Goker-Alpan, William Wilcox, Myrl Holida, Nicola Longo, Derralynn Hughes, Pilar Giraldo, Maria Molnar, Damara Ortiz, Robert Hopkin, Camilla Tondel, Ales Linhart, Patrick Deegan, Ana Jovanovic, Michael Muriello, Bruce Barshop, Virginia Kimonis, Bojan Vujkovac, Albina Nowak, Tarekegn Hiwot, Antonio Pisani, Dominique Germain, Ilkka Kantola, Jasmine Knoll, Ankit Mehta, Stephen Waldek, Einat Almon, Sari Alon, Raul Chertkoff, Rossana Rocco, David Warnock
Format:	Article
Language:	English
Published:	Elsevier 2023-01-01
Series:	Genetics in Medicine Open
Online Access:	http://www.sciencedirect.com/science/article/pii/S2949774423000158

Similar Items

P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51
by: John Bernat, et al.
Published: (2023-01-01)

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
by: Aleš Linhart, et al.
Published: (2023-10-01)

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
by: David G Warnock, et al.
Published: (2015-01-01)

Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease
by: Dominique P. Germain, et al.
Published: (2024-04-01)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
by: Christoph Wanner, et al.
Published: (2020-06-01)

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
by: Goker-Alpan O, et al.
Published: (2016-05-01)

Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events
by: Michael Beck, et al.
Published: (2018-03-01)

Comparative pharmacokinetics and pharmacodynamics of two formulations of agalsidase beta (agalsidase Biosidus) and Fabrazyme® by intravenous infusion in healthy male volunteers
by: Viridiana Berstein, et al.
Published: (2024-12-01)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
by: Michael Beck, et al.
Published: (2015-06-01)

Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
by: Hughes D, et al.
Published: (2021-08-01)

Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa
by: Malte Lenders, et al.
Published: (2022-09-01)

Update on role of agalsidase alfa in management of Fabry disease
by: Uma Ramaswami
Published: (2011-03-01)

Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation
by: André B. P. van Kuilenburg, et al.
Published: (2023-04-01)

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
by: Hollak Carla EM, et al.
Published: (2011-10-01)

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered
by: Ortiz A, et al.
Published: (2015-11-01)

Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype
by: Robert J. Hopkin, et al.
Published: (2020-12-01)

Optimal therapy in Gaucher disease
by: Ozlem Goker-Alpan
Published: (2010-07-01)

Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
by: Kazuya Tsuboi, et al.
Published: (2017-06-01)

A systematic literature review to evaluate the cardiac and cerebrovascular outcomes of patients with Fabry disease treated with agalsidase Beta
by: Gavin Y. Oudit, et al.
Published: (2025-01-01)

Safety and Tolerability of a Shorter Agalsidase Beta Infusion Time in Patients with Classic or Later-Onset Fabry Disease
by: Dominique P. Germain, et al.
Published: (2024-11-01)

Safety of a protocol for reduction of agalsidase beta infusion time in Fabry disease: An Italian multi-centre study
by: Renzo Mignani, et al.
Published: (2022-03-01)

Control of proteinuria with increased doses of agalsidase alfa in a patient with Fabry disease with atypical genotype–phenotype expression
by: Christos Paliouras, et al.
Published: (2015-11-01)

Control of proteinuria with increased doses of agalsidase alfa in a patient with Fabry disease with atypical genotype–phenotype expression
by: Christos Paliouras, et al.
Published: (2015-11-01)

Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol
by: Eleonora Riccio, et al.
Published: (2021-05-01)

Head to toe, in the head
by: Afraz, Arash
Published: (2017)

Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data
by: Feriozzi S, et al.
Published: (2024-04-01)

The head-to-head photodimer of indenoindene
by: Heiner Detert, et al.
Published: (2020-03-01)

P033: Cardiac manifestations of Fabry disease: Insights from a clinic population through cardiac magnetic resonance imaging
by: Darby Manternach, et al.
Published: (2024-01-01)

Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan
by: Makoto Arakawa, et al.
Published: (2024-09-01)

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.
by: Anouk C Vedder, et al.
Published: (2007-07-01)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
by: Ida Vanessa D. Schwartz, et al.
Published: (2018-03-01)

Assigning name headings and writer headings as subjects
by: Tatjana Kovač
Published: (2000-06-01)

Countersunk head screws - Head configuration and gauging
by: 5087 International Organization for Standardization

Countersunk head screws : head configuration and gauging
by: 8096 British Standards Institution, et al.

PRESIDENT OF THE REPUBLIC OF BELARUS – HEAD OR HEAD OF STATE?
by: USM ADMIN
Published: (2024-06-01)

Head and neck oncology: Where are we heading?
by: A K Dewan
Published: (2015-01-01)

Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease
by: Renuka P. Limgala, et al.
Published: (2020-03-01)

Comparative study on incorporation of three recombinant human α-galactosidase A drugs (agalsidases) into cultured fibroblasts and organs/tissues of Fabry mice
by: Takahiro Tsukimura, et al.
Published: (2024-09-01)

Reducing agalsidase beta infusion time in Fabry patients: low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study
by: Renzo Mignani, et al.
Published: (2024-02-01)

HeadSLAM: Pedestrian SLAM with head-mounted sensors
by: Hou, X, et al.
Published: (2022)